The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,966.00
Bid: 1,966.00
Ask: 1,968.00
Change: 10.00 (0.51%)
Spread: 2.00 (0.102%)
Open: 1,963.00
High: 1,994.00
Low: 1,959.00
Prev. Close: 1,956.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Six Brokers Cut Tate & Lyle Price Target

Fri, 14th Feb 2014 10:10

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning:
----------
FTSE 100
----------
JPMORGAN RAISES LLOYDS TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 95 (84) PENCE
----------
SOCGEN RAISES LLOYDS PRICE TARGET TO 94 (86) PENCE - 'BUY'
----------
BERENBERG RAISES PETROFAC TO 'BUY' ('HOLD') - TARGET 1740 (1370) PENCE
----------
BARCLAYS RAISES GLAXOSMITHKLINE PRICE TARGET TO 1575 (1545) PENCE - 'EQUAL WEIGHT'
----------
BERENBERG RAISES GLAXOSMITHKLINE PRICE TARGET TO 1800 (1750) PENCE - 'HOLD'
----------
EXANE BNP CUTS MORRISON TO 'UNDERPERFORM' ('NEUTRAL') - TARGET 200 (230) PENCE
----------
SOCGEN RAISES ROLLS-ROYCE TO 'HOLD' ('SELL') - TARGET 1070 (1150) PENCE
----------
LIBERUM CUTS ROLLS-ROYCE PRICE TARGET TO 1300 (1340) PENCE - 'BUY'
----------
JPMORGAN CUTS TATE & LYLE PRICE TARGET TO 825 (900) PENCE - 'OVERWEIGHT'
----------
CITIGROUP CUTS TATE & LYLE PRICE TARGET TO 800 (900) PENCE - 'BUY'
----------
DEUTSCHE BANK CUTS TATE & LYLE PRICE TARGET TO 900 (1030) PENCE - 'BUY'
----------
CREDIT SUISSE CUTS TATE & LYLE PRICE TARGET TO 700 (800) PENCE - 'NEUTRAL'
----------
PANMURE CUTS TATE & LYLE PRICE TARGET TO 680 (750) PENCE - 'HOLD'
----------
MORGAN STANLEY CUTS TATE & LYLE PRICE TARGET TO 700 (880) PENCE - 'EQUAL-WEIGHT'
----------
CITIGROUP RAISES RIO TINTO PRICE TARGET TO 4200 (4000) PENCE - 'BUY'
----------
JPMORGAN RAISES RIO TINTO PRICE TARGET TO 4600 (4500) PENCE - 'OVERWEIGHT'
----------
MERRILL LYNCH CUTS RIO TINTO TO 'NEUTRAL' ('BUY') - PRICE TARGET 3800 (4200) PENCE
----------
EXANE BNP CUTS RECKITT BENCKISER PRICE TARGET TO 4400 (4600) PENCE - 'UNDERPERFORM,'
----------
SOCGEN RAISES SHIRE PRICE TARGET TO 3870 (3615) PENCE - 'BUY'
----------
CREDIT SUISSE RAISES SHIRE PRICE TARGET TO 3400 (3200) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE CUTS BARCLAYS PRICE TARGET TO 260 (270) PENCE - 'NEUTRAL'
----------
MORGAN STANLEY RAISES AGGREKO PRICE TARGET TO 1300 (1250) PENCE - 'UNDERWEIGHT'
----------
MORGAN STANLEY RAISES BABCOCK INTERNATIONAL PT TO 1550 (1450) PENCE - 'OVERWEIGHT.'
----------
MORGAN STANLEY RAISES BRITISH LAND PRICE TARGET TO 750 (690) PENCE - 'OVERWEIGHT.'
----------
MORGAN STANLEY RAISES HAMMERSON PT TO 560 (540) PENCE - 'EQUAL-WEIGHT'
----------
MORGAN STANLEY RAISES LAND SECURITIES PT TO 1120 (1040) PENCE - 'OVERWEIGHT'
----------
MORGAN STANLEY CUTS INTERTEK PRICE TARGET TO 3300 (3750) PENCE - 'OVERWEIGHT'
----------
FTSE 250
----------
UBS RAISES LADBROKES TO 'BUY' ('NEUTRAL') - TARGET 180 PENCE
----------
JPMORGAN RAISES ENTERTAINMENT ONE PRICE TARGET TO 356 (280) PENCE - 'OVERWEIGHT.'
----------
JPMORGAN RAISES MORGAN ADVANCED MATERIALS PRICE TARGET TO 350 (330) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS OPHIR ENERGY PRICE TARGET TO 400 (440) PENCE - 'OVERWEIGHT'
----------
MERRILL LYNCH CUTS TELECITY GROUP PRICE TARGET TO 595 (650) PENCE - 'UNDERPERFORM'
----------
UBS CUTS TELECITY GROUP PRICE TARGET TO 825 (950) PENCE - 'BUY'
----------
UBS CUTS OXFORD INSTRUMENTS PRICE TARGET TO 1750 (1850) PENCE - 'BUY'
----------
UBS CUTS SERCO PRICE TARGET TO 400 (505) PENCE - 'NEUTRAL'
----------
UBS RAISES BELLWAY PRICE TARGET TO 1930 (1875) PENCE - 'BUY'
----------
PANMURE RAISES BELLWAY PRICE TARGET TO 1639 (1520) PENCE - 'BUY'
----------
DEUTSCHE BANK RAISES LANCASHIRE HOLDINGS PRICE TARGET TO 826 (822) PENCE - 'HOLD'
----------
PANMURE RAISES HIKMA PHARMACEUTICALS PRICE TARGET TO 1375 (1350) PENCE - 'BUY'
----------
MORGAN STANLEY RAISES CARILLION PRICE TARGET TO 325 (315) PENCE - EQUAL-WEIGHT
----------
MORGAN STANLEY RAISES CAPITA GROUP PRICE TARGET TO 1050 (1000) PENCE - 'EQUAL-WEIGHT'
----------
PANMURE CUTS PZ CUSSONS PRICE TARGET TO 430 (445) PENCE - 'BUY'
----------
MORGAN STANLEY RAISES DERWENT LONDON PRICE TARGET TO 3100 (2900) PENCE - OVERWEIGHT.
----------
MORGAN STANLEY RAISES GREAT PORTLAND PRICE TARGET TO 730 (680) PENCE - 'OVERWEIGHT'
----------
MORGAN STANLEY RAISES INTU PROPERTIES PRICE TARGET TO 310 (300) PENCE - 'UNDERWEIGHT'
----------
MORGAN STANLEY RAISES LONDONMETRIC PROPERTY PRICE TARGET TO 135 (127) PENCE - 'UNDERW.'
----------
MORGAN STANLEY RAISES SEGRO PLC PRICE TARGET TO 380 (345) PENCE - 'OVERWEIGHT'
----------
MORGAN STANLEY CUTS SHAFTESBURY PRICE TARGET TO 660 (680) PENCE - 'EQUAL-WEIGHT.'
----------
NUMIS RAISES DE LA RUE TO 'ADD' ('HOLD') - TARGET 854 PENCE
----------
ALL-SHARE AND AIM
----------
MORGAN STANLEY CUTS APR ENERGY PRICE TARGET TO 1350 (1400) PENCE - 'OVERWEIGHT'
----------
PANMURE CUTS PHOENIX IT PRICE TARGET TO 138 (141) PENCE - 'HOLD'
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more
15 Nov 2022 09:58

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
14 Nov 2022 09:25

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
8 Nov 2022 09:39

LONDON BROKER RATINGS: Peel cuts Persimmon; Liberum raises Hammerson

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Nov 2022 11:17

Hikma Pharmaceuticals reiterates 2022 guidance as costs widen

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reiterated annual guidance for all three of its businesses, continuing to expect them to underperform against 2021 due to rising costs.

Read more
3 Nov 2022 11:08

With tighter purse strings, is parity less probable for the pound?

STOXX 600 down 1.1%

*

Read more
3 Nov 2022 09:28

Banks, insurance dodge carnage as real estate stocks sink

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at .

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.